InfuSystem and Ventis ink sales agreement for pain management

The company will offer Ventis Pharma’s patented local anesthetic compound, Endura-KitTM for post-operative surgical and chronic pain management

InfuSystem Holdings, a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced a national sales and marketing agreement with Ventis Pharma, a world leader in advancing surgical and chronic pain management solutions.

The partnership will focus on sales and marketing of Ventis Pharma’s patented Endura-Kit brand of Enduracaine, a local anesthetic compound. Endura-Kit consists of three non-opioid drugs - tetracaine, lidocaine and epinephrine.

Ventis Pharma’s innovative, long-acting, very low-toxicity products are designed to reduce surgical pain and treat chronic pain conditions safely and effectively. These products are cost-effective and available throughout the U.S., to improve the quality of life for all patients.

Richard DiIorio, Chief Executive Officer of InfuSystem, said, “We are pleased to partner with Ventis Pharma in providing a complimentary pain management solution. Endura-Kit™ can be used in conjunction with our InfuBLOCK or as a standalone treatment - providing healthcare professionals and patients an exceptional alternative to oral opioid painkillers. The opioid epidemic in North America is a serious health care crisis. InfuSystem and Ventis Pharma are fully committed to doing our part in helping to reduce the use of oral opioids.”

“Our mission is to provide our customers leading-edge solutions by offering multiple treatment options for delivering quality care. From an operational perspective, this agreement provides the InfuSystem sales team an exciting product that expands the solutions we offer to our customers, generates an additional revenue stream and enhances the effectiveness of each sales call. We believe Ventis Pharma will be an excellent partner leading to a mutually beneficial relationship.”

Tim Patrick, Chief Executive Officer of Ventis Pharma, commented, “Endura-Kit provides anesthesiologists, surgeons and CRNA’s with a better option than the current non-opioid post-op local anesthetic products currently available in the market. We look forward to working closely with InfuSystem and are excited to provide our products and services to our mutual healthcare customers and their patients. This partnership illustrates our unwavering commitment to delivering better medicine to more people while improving the patient’s healthcare experience.”